BACKGROUND AND AIM: An algorithm (GastroPanel) for the non-invasive diagnosis of atrophic gastritis has been previously proposed, based on serum pepsinogen-I, gastrin-17, and Helicobacter pylori (H. pylori) antibodies. The aim of the present study was to evaluate whether serum markers correlate with and predict gastric atrophy in gastroesophageal reflux disease (GERD) patients. METHODS: The baseline data of the prospective ProGERD study, a study on the long-term course of GERD (n=6215 patients), served to select patients with atrophic gastritis diagnosed in biopsies from gastric antrum and corpus, and control cases without atrophy. A total of 208 pairs were matched for age, sex, GERD status (erosive vs non-erosive), presence of Barrett's esophagus, and histological H. pylori status were retrieved. Serum pepsinogen-I, gastrin-17, and H. pylori antibodies were determined using specific enzyme immunoassays. RESULTS: A significant negative correlation was found between the degree of corpus atrophy and the level of serum pepsinogen-I. A previously-reported negative correlation between the degree of antral atrophy and serum gastrin-17 could not be confirmed. The low sensitivity (0.32) and specificity (0.70) of the GastroPanel algorithm were mainly due to over diagnosis and under diagnosis of advanced atrophy in the antrum. CONCLUSION: The diagnostic validity of the GastroPanel algorithm to diagnose gastric atrophy non-invasively is not sufficient for general use in GERD patients.
BACKGROUND AND AIM: An algorithm (GastroPanel) for the non-invasive diagnosis of atrophic gastritis has been previously proposed, based on serum pepsinogen-I, gastrin-17, and Helicobacter pylori (H. pylori) antibodies. The aim of the present study was to evaluate whether serum markers correlate with and predict gastric atrophy in gastroesophageal reflux disease (GERD) patients. METHODS: The baseline data of the prospective ProGERD study, a study on the long-term course of GERD (n=6215 patients), served to select patients with atrophic gastritis diagnosed in biopsies from gastric antrum and corpus, and control cases without atrophy. A total of 208 pairs were matched for age, sex, GERD status (erosive vs non-erosive), presence of Barrett's esophagus, and histological H. pylori status were retrieved. Serum pepsinogen-I, gastrin-17, and H. pylori antibodies were determined using specific enzyme immunoassays. RESULTS: A significant negative correlation was found between the degree of corpus atrophy and the level of serum pepsinogen-I. A previously-reported negative correlation between the degree of antral atrophy and serum gastrin-17 could not be confirmed. The low sensitivity (0.32) and specificity (0.70) of the GastroPanel algorithm were mainly due to over diagnosis and under diagnosis of advanced atrophy in the antrum. CONCLUSION: The diagnostic validity of the GastroPanel algorithm to diagnose gastric atrophy non-invasively is not sufficient for general use in GERD patients.
Authors: William L Neumann; Elizabeth Coss; Massimo Rugge; Robert M Genta Journal: Nat Rev Gastroenterol Hepatol Date: 2013-06-18 Impact factor: 46.802
Authors: Mohammad H Derakhshan; Melina Arnold; David H Brewster; James J Going; David R Mitchell; David Forman; Kenneth E L McColl Journal: Am J Gastroenterol Date: 2016-01-12 Impact factor: 10.864
Authors: Kryssia Rodriguez-Castro; Pellegrino Crafa; Marilisa Franceschi; Lorella Franzoni; Lorenzo Brozzi; Antonio Ferronato; Alice Morini; Lucio Cuoco; Gianluca Baldassarre; Barbara Pertoldi; Francesco Di Mario Journal: Acta Biomed Date: 2022-03-14
Authors: Ji Zhang; Rino Bellocco; Joar Franzén; Ulrika Zagai; Patrik K E Magnusson; Weimin Ye Journal: United European Gastroenterol J Date: 2022-06-22 Impact factor: 6.866
Authors: Adrian G McNicholl; Montserrat Forné; Jesus Barrio; Cristobal De la Coba; Begoña González; Robin Rivera; Maria Esteve; Fernando Fernandez-Bañares; Beatriz Madrigal; Beatriz Gras-Miralles; Angeles Perez-Aisa; Jose M Viver-Pi-Sunyer; Felipe Bory; Merce Rosinach; Carmen Loras; Carlos Esteban; Santos Santolaria; Fernando Gomollon; Julio Valle; Javier P Gisbert Journal: Eur J Gastroenterol Hepatol Date: 2014-09 Impact factor: 2.566
Authors: Jaanus Suumann; Toomas Sillakivi; Živile Riispere; Kari Syrjänen; Pentti Sipponen; Ülle Kirsimägi; Ants Peetsalu Journal: BMC Obes Date: 2018-02-20